|
1
|
MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness.
|
FASEB J
|
2009
|
1.51
|
|
2
|
RAS signaling dysregulation in human embryonal Rhabdomyosarcoma.
|
Genes Chromosomes Cancer
|
2009
|
1.36
|
|
3
|
Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma.
|
Cancer Res
|
2002
|
1.36
|
|
4
|
Malignant pancreatic endocrine tumor in a child with tuberous sclerosis.
|
Am J Surg Pathol
|
2003
|
1.21
|
|
5
|
Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models.
|
Clin Cancer Res
|
2008
|
1.18
|
|
6
|
Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
|
J Cell Physiol
|
2006
|
1.04
|
|
7
|
Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
|
Clin Cancer Res
|
2006
|
1.04
|
|
8
|
Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
|
Clin Cancer Res
|
2008
|
1.03
|
|
9
|
Synergistic post-transcriptional regulation of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) by miR-101 and miR-494 specific binding.
|
PLoS One
|
2011
|
0.99
|
|
10
|
Elevated levels of miR-145 correlate with SMAD3 down-regulation in cystic fibrosis patients.
|
J Cyst Fibros
|
2013
|
0.96
|
|
11
|
Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model.
|
Int J Cancer
|
2009
|
0.95
|
|
12
|
c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
|
Int J Cancer
|
2003
|
0.94
|
|
13
|
Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma.
|
Clin Cancer Res
|
2008
|
0.92
|
|
14
|
Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members.
|
BMC Cancer
|
2014
|
0.89
|
|
15
|
High mobility group A1 is a molecular target for MYCN in human neuroblastoma.
|
Cancer Res
|
2005
|
0.89
|
|
16
|
MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
|
Mol Cancer Res
|
2010
|
0.88
|
|
17
|
Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma.
|
Anticancer Res
|
2008
|
0.88
|
|
18
|
Characterization of Wnt/β-catenin signaling in rhabdomyosarcoma.
|
Lab Invest
|
2013
|
0.87
|
|
19
|
High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.
|
Cancer
|
2006
|
0.87
|
|
20
|
Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.
|
PLoS One
|
2012
|
0.86
|
|
21
|
The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.
|
Neoplasia
|
2012
|
0.85
|
|
22
|
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
|
Cancer Genet Cytogenet
|
2006
|
0.84
|
|
23
|
Long-term follow-up of the "wait and see" approach to localized perinatal adrenal neuroblastoma.
|
World J Surg
|
2013
|
0.84
|
|
24
|
Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases.
|
Virchows Arch
|
2003
|
0.83
|
|
25
|
Activation of p53-dependent responses in tumor cells treated with a PARC-interacting peptide.
|
Biochem Biophys Res Commun
|
2008
|
0.82
|
|
26
|
Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
|
Pediatr Blood Cancer
|
2010
|
0.80
|
|
27
|
Different pattern of matrix metalloproteinases expression in alveolar versus embryonal rhabdomyosarcoma.
|
J Pediatr Surg
|
2004
|
0.80
|
|
28
|
Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report.
|
J Pediatr Hematol Oncol
|
2007
|
0.80
|
|
29
|
Antitumor activity of imatinib mesylate in neuroblastoma xenografts.
|
Cancer Lett
|
2005
|
0.79
|
|
30
|
Vascular endothelial growth factor serum levels in children with newly diagnosed rhabdomyosarcoma.
|
Pediatr Blood Cancer
|
2012
|
0.77
|
|
31
|
Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.
|
Clin Cancer Res
|
2005
|
0.76
|
|
32
|
Bim-dependent apoptosis follows IGFBP-5 down-regulation in neuroblastoma cells.
|
Biochem Biophys Res Commun
|
2006
|
0.76
|
|
33
|
Detection and clinical significance of disseminated tumour cells at diagnosis in bone marrow of children with localised rhabdomyosarcoma.
|
Eur J Cancer
|
2005
|
0.76
|
|
34
|
Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.
|
Int J Cancer
|
2007
|
0.76
|
|
35
|
KIT gene deletion in a gastrointestinal stromal tumor of the small intestine.
|
J Pediatr Gastroenterol Nutr
|
2014
|
0.75
|
|
36
|
Wilms' tumor--lessons and outcomes--a 25-year single center UK experience.
|
Pediatr Hematol Oncol
|
2014
|
0.75
|
|
37
|
Expression of glial cell line-derived neurotrophic factor and neurturin in mature kidney, nephrogenic rests, and nephroblastoma: possible role as differentiating factors.
|
Pediatr Dev Pathol
|
2004
|
0.75
|
|
38
|
Molecular evidence of the independent origin of multiple Wilms tumors in a case of WAGR syndrome.
|
Pediatr Blood Cancer
|
2008
|
0.75
|